Injectable Contraceptive Further Considerations Iris Kapil A NUMBER of articles have appeared in EPW during the past year and a half on the international controversy over the injectable contraceptive. Padma Prakash, in 'Retreat on Depo-Provera?1 reported and endorsed a decision by the United States Food and Drug Administration's Board of Inquiry to recommend against approval for Depo- Provera for use as a contraceptive. Depo- Provera (medroxyprogesterone or DMPA) is the brandname of one, but not the only, three-month injectable contraceptive available for use. Another, NET-EN (norethin- drone enanthate), has been, and continues to be, tested and evaluated in India and elsewhere. NET-EN is now widely used in many countries.
